Tissue Repair Ltd
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration. It develops TR-987, a topical … Read more
Tissue Repair Ltd (TRP) - Net Assets
Latest net assets as of June 2025: AU$13.91 Million AUD
Based on the latest financial reports, Tissue Repair Ltd (TRP) has net assets worth AU$13.91 Million AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$14.57 Million) and total liabilities (AU$662.53K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$13.91 Million |
| % of Total Assets | 95.45% |
| Annual Growth Rate | 69.32% |
| 5-Year Change | -48.61% |
| 10-Year Change | N/A |
| Growth Volatility | 1049.09 |
Tissue Repair Ltd - Net Assets Trend (2020–2025)
This chart illustrates how Tissue Repair Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tissue Repair Ltd (2020–2025)
The table below shows the annual net assets of Tissue Repair Ltd from 2020 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$13.91 Million | -22.88% |
| 2024-06-30 | AU$18.04 Million | -17.56% |
| 2023-06-30 | AU$21.88 Million | -13.64% |
| 2022-06-30 | AU$25.34 Million | -6.41% |
| 2021-06-30 | AU$27.07 Million | +2607.56% |
| 2020-06-30 | AU$999.90K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tissue Repair Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2030383500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$35.04 Million | 251.86% |
| Other Comprehensive Income | AU$2.05 Million | 14.77% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$13.91 Million | 100.00% |
Tissue Repair Ltd Competitors by Market Cap
The table below lists competitors of Tissue Repair Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hiper Global Ltd
TA:HIPR
|
$3.28 Million |
|
TEMPUS RESOURCES LTD
F:4W0
|
$3.28 Million |
|
Carmat
PA:ALCAR
|
$3.28 Million |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
$3.28 Million |
|
Master Pack Group Bhd
KLSE:7029
|
$3.28 Million |
|
SSH Group Ltd
AU:SSH
|
$3.27 Million |
|
Vyome Holdings, Inc.
NASDAQ:HIND
|
$3.27 Million |
|
IQ-AI Limited
PINK:IQAIF
|
$3.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tissue Repair Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,038,674 to 13,911,558, a change of -4,127,116 (-22.9%).
- Net loss of 4,238,501 reduced equity.
- Other comprehensive income increased equity by 111,384.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-4.24 Million | -30.47% |
| Other Comprehensive Income | AU$111.38K | +0.8% |
| Other Changes | AU$1.00 | +0.0% |
| Total Change | AU$- | -22.88% |
Book Value vs Market Value Analysis
This analysis compares Tissue Repair Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.67x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 6.41x to 0.67x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-06-30 | AU$0.02 | AU$0.16 | x |
| 2021-06-30 | AU$0.65 | AU$0.16 | x |
| 2022-06-30 | AU$0.42 | AU$0.16 | x |
| 2023-06-30 | AU$0.36 | AU$0.16 | x |
| 2024-06-30 | AU$0.30 | AU$0.16 | x |
| 2025-06-30 | AU$0.23 | AU$0.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tissue Repair Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -30.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -160.96%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.05x
- Recent ROE (-30.47%) is below the historical average (-23.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -35.22% | -225778.21% | 0.00x | 1.33x | AU$-452.20K |
| 2021 | -3.38% | -599.61% | 0.01x | 1.02x | AU$-3.62 Million |
| 2022 | -26.99% | -3977.17% | 0.01x | 1.02x | AU$-9.37 Million |
| 2023 | -19.08% | -135709.14% | 0.00x | 1.02x | AU$-6.36 Million |
| 2024 | -22.94% | -2718.15% | 0.01x | 1.07x | AU$-5.94 Million |
| 2025 | -30.47% | -160.96% | 0.18x | 1.05x | AU$-5.63 Million |
Industry Comparison
This section compares Tissue Repair Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tissue Repair Ltd (TRP) | AU$13.91 Million | -35.22% | 0.05x | $3.28 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |